Holen Sie sich die Stockscreener-App
10.41
2.87%
0.29
Handel nachbörslich:
10.65
0.24
+2.31%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Viatris Inc Aktie (VTRS) Neueste Nachrichten
Viatris CEO Smith buys $219k in company stock By Investing.com - Investing.com Nigeria
Avantor, Viatris, and Amneal Stocks Trade Up, What You Need To Know - TradingView
VTRS Q2 Deep Dive: Pipeline Progress and Cost Discipline Drive Results Amid Industry Headwinds - ca.finance.yahoo.com
Theravance Sales Jump 83 Percent - The Motley Fool
Bruker, Viatris, Sotera Health Company, Align Technology, and Omnicell Stocks Trade Up, What You Need To Know - Yahoo Finance
Viatris first to win US approval for generic Venofer - The Pharma Letter
Brufen Maker Viatris Fails To Halt Rival's 'Brisen' TM Quest - Law360
Iron Sucrose Competition Expands With Viatris and Amphastar FDA Approvals - insights.citeline.com
Viatris wins FDA nod for generic iron sucrose injection targeting Daiichi’s Venofer - MSN
Viatris Announces Approval of First Generic Iron Sucrose Injection in the U.S. - BioSpace
Why Viatris (VTRS) Is Up 10.3% After Beating Q2 Estimates and Securing FDA Generic Win - simplywall.st
Ampicillin Market Driven by Rising Bacterial Infections - openPR.com
Sector Update: Health Care - MarketScreener
Merz Asks UPC To Bar Viatris Generic MS Drug - Law360
Why Viatris (VTRS) Stock Is Up Today - Yahoo Finance
Viatris Shares Climb Following FDA Clearance of First Generic Iron Sucrose Injection - MSN
Viatris's Generic Iron Sucrose Injection Approval: A Strategic Win for Market Share and Cost-Saving in Healthcare - AInvest
Viatris stock rises after FDA approval of first generic iron sucrose - Investing.com
FDA approves Viatris’ first generic iron sucrose injection for anemia By Investing.com - Investing.com Australia
FDA approves Viatris’ first generic iron sucrose injection for anemia - Investing.com
Viatris announces FDA approval for Iron Sucrose Injection - TipRanks
Carpmaels and A&O Shearman file first SPC suit at UPC for Merz against Viatris - JUVE Patent
Viatris Inc. Reports Strong Q2 2025 Results - TipRanks
EpiPen patent expiry opens new era for innovation - MSN
Viatris Earnings Call: Growth Amid Challenges - The Globe and Mail
Viatris aims for top-half 2025 revenue and EPS guidance while advancing late-stage pipeline - MSN
Research Alert: CFRA Keeps Sell Opinion On Shares Of Viatris Inc. - 富途牛牛
Goldman Sachs Adjusts Price Target on Viatris to $11 From $10, Maintains Neutral Rating - MarketScreener
Will Viatris’ (VTRS) Leadership Moves and Steady Outlook Signal Resilience or Ongoing Transition? - simplywall.st
Viatris Inc. (NASDAQ:VTRS) Q2 2025 Earnings Call Transcript - Insider Monkey
Viatris: Q2 Earnings Snapshot - Connecticut Post
Viatris To Seek FDA Approval For MR-141 In Presbyopia In 2H, 2025Did The Stock Catch Your Eye? - RTTNews
Viatris Inc (VTRS) Q2 2025 Earnings Call Highlights: Strategic Growth Amid Revenue Challenges By GuruFocus - Investing.com Canada
Viatris Reports Mixed Q2 Earnings Amid Pipeline Progress and Operational Challenges - AInvest
Viatris 2025 Q2 Earnings Narrowed Losses Amid Revenue Decline - AInvest
Research Alert: Viatris Reports Q2 Top And Bottom-line Beats - 富途牛牛
Viatris Inc. (VTRS) Stock Forecasts - Yahoo Finance
Viatris Earnings: Solid Results Lift Shares, but We Think There Is a Lot More Upward Momentum Left - Morningstar
Divestitures Muddy Viatris' 2025, but New Launches and Pipeline Support Our Outlook - Morningstar
Xanax-maker Viatris beats quarterly profit, revenue estimates; shares rise - whbl.com
Viatris Inc. stock rises Thursday, outperforms market - MarketWatch
Viatris' Investment Prospects: Navigating Business Model Concerns and Analyst Expectations - AInvest
Viatris (VTRS) Q2 2025 Earnings Call Transcript - Fortune
Viatris Q2 Revenue Beats Expectations, Stock Surges 5.6% YoY Decline - AInvest
Viatris (NASDAQ:VTRS) Beats Q2 Sales Targets, Stock Soars - Yahoo Finance
Earnings call transcript: Viatris beats Q2 2025 estimates, stock rises - Investing.com
Earnings call transcript: Viatris beats Q2 2025 estimates, stock rises By Investing.com - Investing.com Canada
Viatris Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Viatris Inc. shares rise 5.20% intraday after beating quarterly profit and revenue estimates. - AInvest
Viatris Q2 Earnings & Revenues Beat Estimates, Shares Rise - AInvest
Viatris Expects Mid-2025 Revenue and EPS Guidance, Advances Late-Stage Pipeline - AInvest
Viatris (VTRS) Q2 2025 Earnings: Navigating Regulatory Challenges and Strategic Shareholder Returns - AInvest
Viatris Q2 2025: Unraveling Contradictions in Tariffs, Growth Strategies, and Market Opportunities - AInvest
Viatris Stock Rises as Q2 Earnings & Revenues Beat Estimates - TradingView
Viatris Outpaces Expectations Despite India Facility Setback - Finimize
Viatris' Q2 2025 Outperformance: A Case Study in Resilience and Strategic Execution - AInvest
Transcript : Viatris Inc., Q2 2025 Earnings Call, Aug 07, 2025 - MarketScreener
2.52%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):